Posts

STAT+: Congress targets reducing hospital outpatient pa...

House legislators are floating aggressive “site-neutral” bills targeting large h...

FDA’s new plan to study opioids’ effectiveness faces re...

A contentious hearing was the latest chapter in a long-running debate about the ...

STAT+: FDA’s Califf talks cell and gene therapies, abor...

FDA Commissioner Robert Califf took questions on everything from cell and gene t...

STAT+: Senate still hasn’t made hard decisions on lower...

Key lawmakers are scrambling to ensure their competing versions of insulin affor...

Supreme Court delays ruling on abortion pill restrictions

The Supreme Court has delayed its ruling on whether the abortion pill mifepristo...

CDC advisory panel backs changes to Covid vaccination p...

Experts who advise the CDC on vaccination policy informally endorsed a plan Wedn...

STAT+: PhRMA execs paint grim picture of industry under...

PhRMA on Wednesday painted a grim picture for the future of drug development und...

STAT+: Amazon strikes partnership with 3M to advance co...

Amazon has struck a partnership with 3M, which will use the tech giant's Bedrock...

STAT+: STAT-Harris Poll: Most Americans are worried abo...

More than two-thirds of people in the U.S. who know about RSV said they're worri...

STAT+: Pharmalittle: GSK manufacturing workers in the U...

Hundreds of GSK workers have voted to stage a series of walkouts at U.K. manufac...

STAT+: Relay’s breast cancer drug proves tolerable, but...

A drug by Relay Therapeutics shows it can attack breast cancer cells without cau...

STAT+: Leaked study results show a CAR-T from J&J provi...

The CAR-T cancer therapy called Carvykti reduced the risk of relapse by 74% comp...

Discrimination lawsuit against HHMI spotlights barriers...

After Vivian Cheung developed a genetic condition that caused her to start losin...

STAT+: Mindpath seemed like a success story for private...

A STAT investigation of private equity-owned Mindpath Health uncovered a range o...

Opinion: RSV vaccine approval should be a top priority ...

Regulators are considering two highly effective RSV vaccines. What's the holdup?

Opinion: The window is closing to stop deadly drug-resi...

Look to tulip production in the Netherlands for a cautionary tale on the overuse...